Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38542042/
Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent...
A meta-analysis of 15 studies (1708 patients) found that letrozole and exemestane negatively impact lipid profiles in postmenopausal breast cancer patients, warranting monitoring, especially in those with cardiovascular risk factors.
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38392971/
Lipids are a crucial component of the human brain, serving important structural and functional roles. They are involved in cell function, myelination of neuronal projections, neurotransmission, neural plasticity, energy metabolism,...
Lipids play critical roles in brain function and may serve as blood biomarkers for mental illnesses, though further research is needed to clarify their diagnostic potential and effects of psychiatric medications.
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38753448/
ClinicalTrials.gov identifier: NCT03814187.
The ORION-8 study demonstrated that long-term inclisiran use consistently lowered LDL-C by 49.4% with 78.4% achieving LDL-C goals, showing favorable safety and tolerability over 12,000+ patient-years exposure.
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39136871/
Atherosclerotic cardiovascular disease (ASCVD), a leading cause of mortality and morbidity, is associated with a substantial healthcare and economic burden. Reduction of low-density lipoprotein cholesterol (LDL-C) to guideline-recommended goals is...
Inclisiran, a novel LDL-C lowering therapy, offers biannual HCP-administered in-office dosing via the buy-and-bill model, potentially improving ASCVD management by enhancing adherence, timely care, and cardiovascular outcomes.
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38592091/
Atherosclerotic cardiovascular disease (ASCVD) represents a major global health challenge, significantly contributing to mortality rates. This chronic inflammatory condition affecting blood vessels is intricately linked to hypercholesterolemia, with elevated levels...
Atherosclerotic cardiovascular disease, driven by hypercholesterolemia, benefits from lipid-lowering therapies. Novel agents like PCSK9 inhibitors and bempedoic acid enhance LDL-C management, addressing statin limitations and advancing cardiovascular risk reduction strategies.